agilon health Q2 revenue rises 7% to $1.49 billion; raises 2026 guidance
agilon health reported second quarter 2026 total revenue of $1.49 billion, up 7% from a year earlier, and net income of $18 million versus a net loss of $104 million in the second quarter of 2025. The company raised its full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA, though total members on its platform fell 10% to 549,000.
Key points
- Q2 2026 total revenue was $1.49 billion, up 7% from $1.39 billion; net income was $18 million versus a net loss of $104 million in Q2 2025.
- Total members on the platform fell 10% year over year to 549,000 as of June 30, 2026.
- Full-year 2026 guidance: total revenues $5.775 billion to $5.860 billion (previously $5.680 billion to $5.805 billion); medical margin $465 million to $505 million (previously $350 million to $400 million); Adjusted EBITDA $75 million to $9
- Third quarter 2026 guidance: total revenues $1.445 billion to $1.475 billion; Adjusted EBITDA negative $5 million to positive $5 million.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.